Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Tb52.5
TB-500 – Forschung
Überwiegend Mechanismus / Beobachtung
16 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu TB-500 sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 1990–2026 mit einer typischen Studiengröße von 18 Teilnehmenden.
Basierend auf 16 Studien · 2 RCTs · 701 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Vision & eye health
Überwiegend Mechanismus / Beobachtung3 Studien
Wound & ulcer healing
Zu wenige bewertete Studien2 Studien
Cardiac repair & heart
Zu wenige bewertete Studien2 Studien
Hair & nails
Zu wenige bewertete Studien1 Studie
Tumor biology & cancer risk
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
5 Studien in den letzten 5 Jahren
199020082026
1Systematische Übersicht2026
Despite the popularity of these peptides in mainstream media and among patients, significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients.
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · The American journal of sports medicine (2026)
CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies.
GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions.
Conclusion While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides.
Peptide therapeutics, therefore, represent a developing research domain whose relevance to thyroid care remains to be established through rigorous investigation.
Mazza AD. · Integrative medicine (Encinitas, Calif.) (2026)
Safety profiles vary across peptide classes, and clinical use remains largely investigational in the context of thyroid disease.
This review presents potential biologic pathways linking peptide activity to immune and metabolic aspects of thyroid disorders, as well as regulatory and ethical considerations surrounding emerging peptide applications.
Substantial evidence gaps persist, and well-designed thyroid-focused clinical trials are needed to clarify safety, efficacy, and appropriate clinical roles.
3Beobachtungsstudie2026
Key challenges moving forward include validating efficacy in additional clinically relevant models, overcoming peptide instability and completing comprehensive safety assessments.
Di H, Huang J, Zhang D, Ni F, Zheng R, Geng H. · Peptides (2026)
To reconcile disparate findings, we propose conceptual frameworks that consider bidirectional effects on fibrosis and model-dependent mechanisms.
Finally, translational opportunities are appraised with attention to pharmacokinetics, peptide stability and delivery strategies.
Key challenges moving forward include validating efficacy in additional clinically relevant models, overcoming peptide instability and completing comprehensive safety assessments.
Thymosin β4 binds to actin and promotes cell migration, including the mobilization, migration, and differentiation of stem/progenitor cells, which form new blood vessels and regenerate the tissue.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. · Expert Opin Biol Ther (2012)
Review of thymosin β-4 (Tβ4) as a naturally occurring repair/regeneration peptide released after injury
Tβ4 sequesters G-actin, promotes cell migration and angiogenesis, and reduces inflammation and scarring
Surveys proposed therapeutic uses in skin, eye, heart and brain — largely preclinical with early clinical work
Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects (p = 0.0656), indicating a strong efficacy trend.
Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. · Int J Mol Sci (2022)
Randomized, placebo-controlled, double-masked Phase 3 trial of 0.1% RGN-259 (pharmaceutical thymosin β-4) eye drops for persistent epithelial defects in Stage 2-3 neurotrophic keratopathy
Complete healing at 4 weeks in 6/10 treated vs 1/8 placebo (p = 0.0656, trend); significant healing by day 43 (p = 0.0359) with no recurrence in the treated group
Treated subjects had significant improvements in ocular discomfort, foreign-body sensation and dryness; no significant adverse effects
At day 56, the RGN-259-treated group (12 eyes) had 35.1% reduction of ocular discomfort compared with vehicle control (6 eyes) (P = 0.0141), and 59.1% reduction of total corneal fluorescein staining compared with vehicle control (P = 0.0108).
Sosne G, Dunn SP, Kim C. · Cornea (2015)
Small multicenter, randomized, double-masked, placebo-controlled Phase 2 trial of 0.1% RGN-259 (thymosin β-4) eye drops in 9 patients with severe dry eye
Significant reductions in ocular discomfort (OSDI) and corneal fluorescein staining vs vehicle at multiple time points, persisting 28 days post-treatment
RGN-259 was safe and well tolerated and met key efficacy objectives (NCT01393132)